Goldman Sachs’s Pyxis Oncology PYXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $247K | Buy |
224,274
+63,444
| +39% | +$69.8K | ﹤0.01% | 4625 |
|
|
2025
Q1 | $158K | Sell |
160,830
-23,872
| -13% | -$23.4K | ﹤0.01% | 4724 |
|
|
2024
Q4 | $288K | Buy |
184,702
+45,570
| +33% | +$71.1K | ﹤0.01% | 4546 |
|
|
2024
Q3 | $511K | Buy |
139,132
+21,884
| +19% | +$80.3K | ﹤0.01% | 4106 |
|
|
2024
Q2 | $388K | Sell |
117,248
-219,443
| -65% | -$726K | ﹤0.01% | 4084 |
|
|
2024
Q1 | $1.43M | Buy |
+336,691
| New | +$1.43M | ﹤0.01% | 3392 |
|
|
2023
Q3 | – | Sell |
-45,974
| Closed | -$118K | – | 4900 |
|
|
2023
Q2 | $118K | Buy |
45,974
+10,550
| +30% | +$27K | ﹤0.01% | 4537 |
|
|
2023
Q1 | $142K | Buy |
+35,424
| New | +$142K | ﹤0.01% | 4612 |
|
|
2022
Q3 | – | Sell |
-12,882
| Closed | -$31K | – | 5627 |
|
|
2022
Q2 | $31K | Buy |
+12,882
| New | +$31K | ﹤0.01% | 5369 |
|